Gyros and DI Biotech Sign Distribution Agreement for the Korean Market
News Nov 27, 2009
Gyros® AB announces the signing of a distribution agreement with DI Biotech, a supplier to the Korean life-science market.
Under the terms of the agreement, DI Biotech will market and provide full support for Gyros’ proprietary technology, Gyrolab®, to the Korean pharmaceutical, biotech, CRO and CMO industries.
Gyrolab has become established as the preferred technology for high-performance immunoassays for the development of biotherapeutics. The technology is increasingly employed by leading pharmaceutical and biotech companies, and their contracted service organizations, in their drug development process and clinical trials, in both Europe and the USA.
As a result of this success, the company has now decided to expand its business into Asia, with Korea as its initial market.
“We are very happy to have DI Biotech representing our products in the Korean market”, states Erik Wallden, CEO and President of Gyros. “It’s an organization with longstanding experience, presence, and a solid position as a leading supplier of high-tech tools to the biotech market. Korea is committed to the growing biotherapeutics development segment and we are looking forward to supplying enabling technology to various ongoing initiatives in the country,” he concludes.
Study Extends Potential of Personalized Cell-based ImmunotherapiesNews
New methods developed for the study could be applied to devise personalized, cell-based immunotherapies for epithelial ovarian cancer or other types of tumorsREAD MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Hope for Hot Flushes: New Class of Menopause Drugs Reduces SeverityNews
A new class of experimental drugs reduces hot flushes in menopausal women by almost three-quarters in just three days. The new analysis, published in the journal Menopause, also revealed sleep and concentration significantly improved in the three-day window.